The End of the X-waiver: Excitement, Apprehension, and Opportunity

References

1. 1.↵
   1. Cavitt L,
   2. St Louis J,
   3. Barr WB,
   4. et al

   . Teaching residents to prescribe buprenorphine for opioid use disorder: Insights from a community-based residency program. J Subst Abuse Treat 2022;132:108621.

   OpenUrl
2. 2.↵
   1. Mattson CL,
   2. Tanz LJ,
   3. Quinn K,
   4. Kariisa M,
   5. Patel P,
   6. Davis NL

   . Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR Morb Mortal Wkly Rep 2021;70:202–7.

   OpenUrlPubMed
3. 3.↵
   S. 445—Mainstreaming Addiction Treatment Act of 2021. 2021 February 25 [accessed 2023 January 24]; Available at: https://www.congress.gov/bill/117th-congress/senate-bill/445/text.
4. 4.↵
   Text—H.R.2067—117th Congress (2021–2022): MATE Act of 2021. 2021 October 19 [accessed 2023 1/24/2023]; Available at: https://www.congress.gov/bill/117th-congress/house-bill/2067/text.
5. 5.↵
   1. Rosenblatt RA,
   2. Andrilla CHA,
   3. Catlin M,
   4. Larson EH

   . Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med 2015;13:236.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Andrilla CHA,
   2. Moore TE,
   3. Patterson DG,
   4. Larson EH

   . Geographic distribution of providers with a DEA waiver to prescribe buprenorphine for the treatment of opioid use disorder: a 5-year update. J Rural Health 2019;35:108–12.

   OpenUrlCrossRef
7. 7.↵
   1. Spetz J,
   2. Hailer L,
   3. Gay C,
   4. et al

   . Changes in US clinician waivers to prescribe buprenorphine management for opioid use disorder during the COVID-19 pandemic and after relaxation of training requirements. JAMA Netw Open 2022;5:e225996.

   OpenUrl
8. 8.↵
   1. McGinty EE,
   2. Stone EM,
   3. Kennedy-Hendricks a,
   4. et al

   . medication for opioid use disorder: a national survey of primary care physicians. Ann Intern Med 2020;173:160–2.

   OpenUrl
9. 9.↵
   1. Peterson LE,
   2. Morgan ZJ,
   3. Borders TF

   . Practice predictors of buprenorphine prescribing by family physicians. J Am Board Fam Med 2020;33:118–23.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Olfson M,
    2. Zhang V,
    3. Schoenbaum M,
    4. et al

    . Buprenorphine treatment by primary care providers, psychiatrists, addiction specialists, and others. Health Aff (Millwood) 2020;39:984–92.

    OpenUrl
11. 11.↵
    1. Physicians TAoF

    . Family medicine residency programs are critical in training Texas’ physician workforce. [accessed 2023 February 9]; Available at: https://www.tafp.org/Media/Default/Downloads/advocacy/Support_FM_Residency_Expansion.pdf.
12. 12.↵
    1. Tong S,
    2. et al

    . assessment of addiction medicine training in family medicine residency programs: a CERA study. Fam Med 2017;49:537–43.

    OpenUrl
13. 13.↵
    1. Mital S,
    2. Wolff J,
    3. Carroll JJ

    . The relationship between incarceration history and overdose in North America: a scoping review of the evidence. Drug Alcohol Depend 2020;213:108088.

    OpenUrl
14. 14.↵
    1. Kimmel SD,
    2. Rosenmoss S,
    3. Bearnot B,
    4. et al

    . Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts. J Addict Med 2021;15:20–6.

    OpenUrl
15. 15.↵
    Department of Justice (Civil rights division). The Americans with Disabilities Act and the opioid crisis: combating discrimination against people in treatment or recovery. 2022 4/5/2022 [accessed 2023 February 6]; Available at: https://archive.ada.gov/opioid_guidance.pdf.
16. 16.↵
    1. Andraka-Christou B,
    2. Gordon AJ,
    3. Bouskill K,
    4. et al

    . Toward a typology of office-based buprenorphine treatment laws: themes from a review of state laws. J Addict Med 2022;16:192–207.

    OpenUrl
17. 17.↵
    1. Fiellin DA,
    2. Pantalon MV,
    3. Chawarski MC,
    4. et al

    . Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006;355:365–74.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Carroll KM,
    2. Weiss RD

    . The role of behavioral interventions in buprenorphine maintenance treatment: a review. Am J Psychiatry 2017;174:738–47.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Lai B,
    2. Croghan I,
    3. Ebbert JO

    . Buprenorphine waiver attitudes among primary care providers. J Prim Care Community Health 2022;13:21501319221112272.

    OpenUrl
20. 20.↵
    1. Wakeman SE

    . Opioid use disorder diagnosis and management. N Engl J Med Evidence 2022;1:EVIDra2200038.

    OpenUrl
21. 21.↵
    1. Sue KL,
    2. Cohen S,
    3. Tilley J,
    4. et al

    . A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era. J Addict Med 2022;16:389–91.

    OpenUrl
22. 22.↵
    1. Demuynck S

    . A generation ready for change: preparing for the deregulation of medications for opioid use disorder in undergraduate medical education. Acad Med 2023;98(4):440–443.

    OpenUrl
23. 23.↵
    1. Tesema L,
    2. Marshall J,
    3. Hathaway R,
    4. et al

    . Training in office-based opioid treatment with buprenorphine in US residency programs: A national survey of residency program directors. Subst Abus 2018;39:434–40.

    OpenUrl
24. 24.↵
    1. Gordon AJ,
    2. Kenny M,
    3. Dungan M,
    4. et al

    . Are x-waiver trainings enough? Facilitators and barriers to buprenorphine prescribing after x-waiver trainings. Am J Addict 2022;31:152–8.

    OpenUrl
25. 25.↵
    Massachusetts Consultation Service for Treatment of Addiction and Pain (MCSTAP). [accessed 2023 February 6]; Available at: https://www.mcstap.com/.
26. 26.↵
    University of California, S.F. National Clinician Consultation Center. Substance Use Warmline. [accessed 2023 February 6]; Available at: https://nccc.ucsf.edu/clinician-consultation/substance-use-management/.
27. 27.↵
    1. Sokol RG,
    2. Pines R,
    3. Chew A

    . Multidisciplinary approach for managing complex pain and addiction in primary care: a qualitative study. Ann Fam Med 2021;19:224–31.

    OpenUrlAbstract/FREE Full Text
28. 28.
    1. Disorder ESU

    . The Mainstreaming Addiction Treatment Act: a historic reform. 2023 [accessed 2023 1/24/2023]; Available at: https://www.endsud.org/mat-act-history/#mat-act.